Related references
Note: Only part of the references are listed.Clinical insights into the origins of thrombosis in myeloproliferative neoplasms
Alison R. Moliterno et al.
BLOOD (2021)
Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival
Ghaith Abu-Zeinah et al.
LEUKEMIA (2021)
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
Heinz Gisslinger et al.
LANCET HAEMATOLOGY (2020)
Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Elsa Bernard et al.
NATURE MEDICINE (2020)
Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension
Heinz Gisslinger et al.
BLOOD (2020)
Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon α-treated polycythemia vera patients
Elizabeth Margolskee et al.
HAEMATOLOGICA (2017)
Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon α-treated polycythemia vera patients
Elizabeth Margolskee et al.
HAEMATOLOGICA (2017)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials
John Mascarenhas et al.
HAEMATOLOGICA (2014)
Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F
Pontus Lundberg et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
Giovanni Barosi et al.
BLOOD (2013)
The in vitro effects of interferon-gamma, interferon-alpha, and tumour-necrosis factor-alpha on erythroid burst-forming unit growth in patients with non-leukaemic myeloproliferative disorders
Edward J. Kanfer et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Interferon-α targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway
Min Lu et al.
EXPERIMENTAL HEMATOLOGY (2010)
The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis
Juergen Thiele et al.
Current Hematologic Malignancy Reports (2008)
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
R Marchioli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
